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ABSTRACT
Background In the photodynamic therapy (PDT) of non-aggressive basal cell carcinomas 
(BCCs), 5-aminolevulinic acid nanoemulsion (BF-200ALA) has shown non-inferior efficacy 
when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl 
aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the 
first study using HAL-PDT in the treatment of BCCs. 
Objectives To compare the histological clearance, tolerability (pain and post-treatment reaction), 
and cosmetic outcome of MAL, BF-200 ALA, and low-concentration HAL in the PDT of non-
aggressive BCCs. 
Methods Ninety-eight histologically verified non-aggressive BCCs met the inclusion criteria, and 
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PDT in two repeated treatments with MAL, BF-200 ALA, or HAL. Efficacy was assessed both 
clinically and confirmed histologically at three months by blinded observers. Furthermore, 
cosmetic outcome, pain, post-treatment reactions fluorescence, and photobleaching were 
evaluated.
Results According to intention-to-treat analyses, the histologically confirmed lesion clearance was 
93.8% (95% confidence interval [CI] = 79.9–98.3) for MAL, 90.9% (95% CI = 76.4–96.9) for BF-
200 ALA, and 87.9% (95% CI = 72.7–95.2) for HAL, with no differences between the arms 
(p=0.84). There were no differences between the arms as regards pain, post-treatment reactions, or 
cosmetic outcome. 
Conclusions PDT with low-concentration HAL and BF-200 ALA have a similar efficacy, 
tolerability, and cosmetic outcome compared to MAL. HAL is an interesting new option in 
dermatological PDT, since good efficacy is achieved with a low concentration.
Registration numbers: EudraCT with 2014-002746-50 and clinicaltrial.gov with NCT02367547.
INTRODUCTION
The incidence of basal cell carcinoma (BCC), especially the superficial subtype (sBCC) is 
rising1,2. BCC is as common as all other malignancies combined, and thus causes remarkable 
health care costs3,4. The sBCC and the thin nodular BCC (nBCC) are often classified as low-risk 
tumours, and they can be treated with non-surgical options5, i.e. photodynamic therapy (PDT), 
imiquimod or 5-fluorourasil (5-FU), where imiquimod has superior efficacy 6-7. The advantages of 
PDT include a superior cosmetic outcome and short application and down times8,9.
PDT uses a combination of light, a photosensitizing agent (an exogenous source for 
photoactive protoporphyrin IX, PpIX), and oxygen to generate a radical oxygen species that cause 
cell apoptosis and necrosis10,11. Of these factors, PpIX production in particular seems to be related 
to cell death12. Thus, changing the prodrug of PpIX could be an effective way to enhance the 
reaction. 
The PpIX produced can be measured as the fluorescence of a photosensitizer13. 
Fluorescence and especially photobleaching (i.e. the difference in fluorescence measured before 
and after illumination) correlate with the accumulation of PpIX and with efficacy14,15.
5-aminolevulinic acid (5-ALA) was the first photosensitizer in PDT of skin malignancies 
with selectivity in the tumour tissue10. The esters of 5-ALA like methyl aminolevulinate (MAL) 
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nanoemulsion of 5-ALA (BF-200 ALA) at a 10% concentration a greater fluorescence was 
detected after incubation time, when compared to 20% 5-ALA16. In addition, BF-200 ALA was 
shown to penetrate deeper in an ex vivo skin model, when compared to MAL17. The efficacy of 
BF-200 ALA is shown to be non-inferior compared to MAL in PDT of non-aggressive BCCs18. 
Hexyl aminolevulinate (HAL) is a long-chain lipophilic 5-ALA ester, capable to produce 
significantly higher fluorescence intensities in the human epidermis and superficial dermis, when 
compared to MAL – though in the mid and deep dermis the intensity is only slightly higher19. An 
equal fluorescence intensity is achieved in the rat skin using HAL2% and MAL20%20. HAL, BF-
200 ALA and MAL seem to be equally tolerated when applied on normal human skin21.
This prospective trial aims to compare the efficacy and tolerability (i.e. pain and post-
treatment-reaction) of MAL, BF-200 ALA, and low-concentration HAL in the PDT of non-
aggressive BCCs.
Materials and methods 
The protocol complied with the Declaration of Helsinki and was approved by the Ethics 
Committee of Tampere University Hospital and by the Finnish Medicines Agency. Written 
informed consent was obtained from all participants. Patients were recruited from those referred to 
the Department of Dermatology and Allergology at Päijät-Häme Social and Health Care Group, 
Lahti, Finland, between March 2015 and September 2018.
The three parallel arms were MAL16% (Metvix®, Galderma Norcid AB), and BF-200 
ALA7.8% (Ameluz®, Biofrontera), and HAL2% (mixture of Hexvix® powder, Photocure ASA, 
and unguentum M cream, Allmirall Hermal GmbH) with allocation ratio of 1:1:1. Of these, MAL 
and BF-200 ALA are approved for the PDT of non-aggressive BCCs, and HAL is approved for the 
photodynamic diagnosis of uroepithelial cancer and the treatment of cervical dysplasia by the 
European Medicines Agency.
Inclusion and exclusion criteria
Patients over 18 years old presenting with a superficial BCC clinically were enrolled. Exclusion 
criteria included pregnancy, lactation, allergy/intolerance to the photosensitizers used, porphyria, 
and photosensitivity. 
The target lesions had to be located on the trunk or extremities. Lesions located on the face 
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lesions located at least 10 cm apart from each other to minimize mixing up the photosensitizers22. 
The target BCCs were included according to clinical inspection with a dermatoscope, and 
randomized to one of the three arms at the recruitment visit. However, a diagnostic biopsy was 
taken from all included lesions prior to treatment. Lesions with some other histopathology than 
BCC were excluded from the analyses. Only lesions confirmed to be non-aggressive, i.e. a 
superficial or thin nodular – defined as growing into the epidermal-dermal junction or the most 
upper third of the dermis – could be included for analyses. 
Outcomes
The primary outcome was histologically verified clearance at three months. The secondary 
outcomes were pain during the illumination with the use of a long-acting local anaesthetic prior to 
pre-handling, post-treatment reaction, cosmetic outcome, and fluorescence/photobleaching. 
Power calculations, randomization and treatment allocation
In the power calculations (alpha=0.05, power=0.85, delta=0.30), it was assumed that BF-200 
ALA/HAL would be superior to MAL, as MAL has an efficacy of 72.8% at twelve months9, 
although the efficacy might be even lower in a group aged over 60 years23. Thus the efficacy of 
MAL was assumed to be 65%. Same delta-value was used both for BF-200 ALA and HAL. Thus, 
the needed sample size was 31 lesions/arm. The initial set (93 lesions) was randomized using a 
web-based validated program, Research randomizer.org®. As the trial proceeded, we noticed of 
the other histology than BCC being notable, and performed another set of randomization (24 
lesions) with closed envelopes (at the moment troubles using Research randomizer®). In total, 117 
lesions (39/arm) were randomized, Figure 1. 
Protocol
Prior to treatment (performed by M.S. and J.R.), the lesions were assessed with a dermatoscope 
(Dermlite® DL3 or DL3N, 3GenCA, USA, or Heine Delta 20T®). Treatment areas including the 
lesion, a 5 mm margin, and a biopsy site were marked on plastic sheets with scaling (1x1mm 
squares). A diagnostic 3 mm punch biopsy was taken prior to curettage at the first session (PDT I), 
and local anaesthetics (1:1 mixture of lidocaine 10mg/ml cum epinephrine 10 μg/ml to ropivacaine 
7.5mg/ml) were infiltrated prior to any procedures at both sessions. Curettage i.e. removing 
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aluminium chloride was used for haemostasis, and in PDT I the biopsy site was closed with a 
transparent stitch (Monocryl 4-0). Thereafter a 1 mm thick layer of photosensitizer (treatment area 
calculated from plastic sheets in mm2, photosensitizer scaled with 1 mg/mm2 dosing) was applied 
to the treatment area followed by three hours occlusion with a light-impermeable cover before 
illumination (Aktilite, CL128, Galderma, 37 J/cm2 per session). All lesions were illuminated with 
the same total time of 7 min and 24 seconds, but recording of pain and illuminating together took 
approximately 8 minutes of time. The second session (PDT II) followed 8–14 days after PDT I. 
Figure 2 represents an example case.
Assessment of efficacy
At the three-month follow-up visit an experienced dermatologist (M.G.), blinded for treatment, 
evaluated all lesions with inspection and with a dermatoscope, and took 3 mm control punch 
biopsies near the diagnostic biopsy site using the marked plastic sheets as guidance. Additional 3 
mm punch biopsies were taken from clinically suspicious sites if needed. Non-responsive lesions 
were completely excised as a second line treatment, which allowed us to evaluate if a mixed 
histology with aggressive features would exist. An experienced pathologist (T.T.), blinded for 
treatment, assessed all histopathological specimens.
Assessment of the treatment tolerability and cosmetic outcome
Pain was assessed by patients, blinded for photosensitizer, using a visual analogue scale (VAS)24 
at the beginning, in the middle, and in the end of each illumination. No other pain management 
was used. For our analyses we named the difference of VAS in the middle and at the beginning as 
4 min, and the difference of VAS in the end and at the beginning as 8 min. Thus we acknowledged 
that the pain experienced by the patient at the beginning of the illumination could be something 
else than zero. 
Post-treatment reactions (oedema, erythema, erosion, and crust formation) were 
photographed 8–14 days after PDT I and assessed afterwards on a five-point scale 
(none/minimal/mild/moderate/severe) by the blinded observer (M.G.). The cosmetic outcome was 
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Fluorescence images were taken at the beginning and end of illumination using a digital camera 
(Canon Ixus 130, 14.1 megapixel with the set-up ISO800, FW 2.8, no zoom), a Wood’s light 
(Philips Burton®, Somerset, USA, kept hand-held at a distance of about 8 cm) and a yellow filter 
lens (Hoya HMC, yellow-green xo, attached to the top of the Wood’s light), as used by 
Neittaanmäki-Perttu et al.21 The photosensitizer was removed with saline solution before imaging. 
Statistical analyses and calculations of fluorescence
Statistical analyses were conducted with a professional statistician using SPSS 23.0 (IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.), or a mathematician (I.P.) with 
Python 3.6 using Numpy and Scipy libraries. 
As statistical methods, Fisher’s exact test was used to compare the efficacy, post-treatment 
reactions, and the cosmetic outcome. As regards pain, the comparison between the arms was 
performed with the Kruskall–Wallis test, and the comparison between the sessions in each arm 
with the Wilcoxon Signed Rank Test. For fluorescence and photobleaching, the ANOVA test was 
used to compare the treatment arms, and to calculate the correlation between the histological 
clearance and the fluorescence/photobleaching, the Chi-squared was used.
Fluorescence images were processed semi-automatically using affine transformation and 
manually selected matching points by a mathematician (L.A.) with Python 3.6. The intensity was 
extracted in the red light channel to achieve arbitrary units (A.U.) for fluorescence and 
photobleaching (as the absolute difference of the mean fluorescence before and after illuminating).
Results
Altogether 98 histologically verified non-aggressive BCC (in 57 patients) were included to the 
study, but there were three dropouts. Thus 54 patients completed the study with 95 non-aggressive 
BCCs (Figure 1). Table 1 represents the patients and lesion characteristics. In total, six residual 
lesions were found at three months follow-up (1/31 in MAL, 3/33 in BF-200 ALA, and 2/31 in 
HAL). In the final excision of non-responsive lesions, there were no aggressive subtypes. 
Lesion clearance with intention-to-treat analyses
Among the 98 non-aggressive BCCs, i.e. including the dropouts, the histologically verified 
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ALA, and 87.9% (95% CI = 72.7–95.2) for HAL (in the comparison of the arms; p=0.84). Thus, 
there were no differences between the arms in terms of efficacy.
Tolerability and cosmetic outcome
Pain results for the 95 BCCs of the 54 patients who completed the study are reported in Figure 3A. 
No differences were found in pain between the arms during illumination (MAL vs BF-200 ALA 
vs HAL; PDT I 4 min p=0.21, 8 min p=0.18; PDT II 4 min p=0.47, 8 min p=0.87). In the HAL 
group, the second session was more painful than the first session (PDT I vs PDT II; 4 min 
p=0.006, 8 min p=0.005). There was no difference in pain between the sessions in the other arms 
(PDT I vs PDT II; MAL 4 min p=0.17, 8 min p=0.79; BF-200 ALA 4 min p=0.45, 8 min p=0.43). 
Among the 95 BCCs, no differences were either found in the post-treatment reactions 
(p=0.49; Figure 3B, and Figure 2E). There was one treatment-related withdrawal from the trial, as 
one patient from the MAL group experienced remarkable swelling, oedema, erythema, and 
haematoma in the treatment area after PDT I, and refused to attend PDT II. 
Among the 95 BCCs, the cosmetic outcome was regarded as good/excellent in 77.4% of 
the lesions in the MAL group, 75.7% in the BF-200 ALA group, and 61.3% in the HAL group, 
with no differences between the arms (p=0.61; Figure 3C, and Figure 2F).
Fluorescence and photobleaching
In total, fluorescence images were available from 84 lesions in 49 patients from PDT I, and 
respectively from 91 lesions in 51 patients from PDT II. At the beginning of the illumination, 
fluorescence was lower in HAL2% compared to MAL16% and BF-200 ALA7.8% (PDT I p=0.043 
and PDT II p=0.043). However, there was no statistical significant difference in photobleaching 
between the arms (PDT I p=0.09 and PDT II p=0.42). We found no correlation between the 
histological clearance and the photobleaching (PDT I p=0.40, PDT II p=0.77) or fluorescence 
(PDT I p=0.77, PDT II p=0.55). Fluorescence and photobleaching showed a wide variation. 
Discussion
To our knowledge, this is the first trial using HAL-PDT for non-aggressive BCCs. Morrow et al. 
have earlier suggested that HAL is more effective in equimolar doses compared to MAL and 5-
ALA25. Dögnitz et al. reported that HAL could be used in smaller concentrations to achieve a 
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Kiesslich et al. demonstrated for 5-ALA, MAL, and HAL in vitro that after a certain threshold 
limit, the intracellular PpIX concentration doesn’t rise by increasing the concentration of the 
prodrug, but under this threshold the concentration matters, also the incubation time of the 
prodrug27. There are many variables in PDT, and thus the protocol used can affect the efficacy28,29. 
Consequently, the optimal concentration and protocol for HAL-PDT of non-aggressive BCCs is 
still unexplored.
In a recent multi-centre trial, Morton et al. reported a three-month clinical clearance of 
91.8% for MAL and 93.4% for BF-200 ALA in the PDT of non-aggressive BCCs18. In another 
multi-centre trial, Arits et al. reported clinical clearance of 84.2% at three months for MAL-PDT9. 
We and Morton et al. used curettage, but Arits et al. reported ‘a non-traumatic surface 
preparation’. In our experience, some small trauma can occur in curettage, and physical pre-
treatment in PDT enhances the PpIX uptake30,31. 
Morton et al. have shown the similar tolerability of BF-200 ALA and MAL18. 
Interestingly, HAL seems to have a more precise effect on the site of application compared to 5-
ALA on mice skin, and this could be beneficial in terms of post-treatment reactions32. 
Neittaanmäki-Perttu et al. reported that on healthy human skin, HAL2% caused a similar erythema 
as BF-200 ALA7.8% and MAL16%, and in terms of pain, there was a significant difference in the 
respective comparison21. In our results, for BCC we did not found any differences between the 
arms in terms of adverse events. 
As regarding pain, Lindeburg et al. have reported that PDT II is more painful than PDT I 
when treating actinic keratosis and sBCC with MAL-PDT33. Perhaps due to the small sample size, 
this difference was found only for HAL in our results. Our mean and median VAS score was 2.3 
at its highest. Interestingly, Morton et al. had a highest mean pain score (on a 1–10 scale) of 4.5 
without analgesia, despite the use of a BF-RhodoLED (Biofrontera) light source with reduced pain 
levels compared to Aklite (Galderma)34. Thus, it seems that a long-acting local anaesthetics prior 
to pre-handling could be effective in pain management – though this differs from the European 
PDT guidelines35. Previously, nerve blocking has been shown to be an effective option, whereas 
topical analgesia has not36. Our method should be studied more closely in a prospective and 
randomized setting, including in carcinomas in situ and head locations, where pain can be a major 
obstacle37. 
In PDT, the use of local analgesia can have a potential impact on efficacy through 
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this. Infiltration of local anaesthetics has earlier been used during illumination with 
lidocaine/prilocaine cum ropivacaine, and also cum epinephrine, with good treatment success38,39. 
However, our pain management protocol didn’t affect the results.
We found a good/excellent cosmetic outcome in 71.6% of all the lesions at three months. 
We did not achieve the results of Jansen et al.8 (the same trial as by Arits et al.), who reported a 
good/excellent cosmetic outcome in MAL-PDT for 89.5% of patients at five years. However, the 
cosmetic outcome tends to improve over time18. 
Non-surgical options provide a cost-effective alternative to surgery in the treatment of non-
aggressive BCCs40, and patients with multiple lesions or facial lesions are willing to risk the 
recurrence rate for a better cosmetic outcome41. The advantages of PDT include the cosmetic 
outcome8, the shorter application and down times, and the mode of delivery9, but the major 
disadvantage is the lower efficacy compared to imiquimod6. However, the topical creams demand 
good patient compliance and correct patient selections, as the creams are applied by the patient at 
home for a number of weeks. Regarding the economic aspect of low-concentration HAL, there 
could be benefits in the manufacture of the cream, as only a low concentration is demanded. 
Interestingly in the daylight PDT of thin actinic keratosis, a similar efficacy was achieved with 
HAL0.2% as compared to MAL16%42.
The strengths of our study are the investigator-initiated double-blinded design, 
histopathological confirmation in addition to the clinical evaluation, and the complete excision of 
the non-responsive lesions to examine the possible underlying mixed histologies as the cause for 
treatment failure. We assumed our patients would be over 60 years, and this corresponded to our 
material quite accurately; only 6/54 of the analysed patients were under 60 years.
The limitations of our study design are a limited sample size and optimistic assumptions in 
the power calculations. The taking of diagnostic biopsies at the first treatment session should also 
be considered a limitation, since these could potentially lead to lesion resolution due to 
inflammation induced by the biopsy. A limitation of the pain analyses was the absence of a control 
group for local anaesthetics. Furthermore, the summation of pain may have occurred in patients 
with multiple lesions, but in our protocol lesions (not patients) were randomized, and thus the 
possible effect should be quite equal for all arms. A major limitation in the 
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In conclusion, HAL is an interesting new option for dermatological PDT. The efficacy and 
tolerability of low-concentration HAL was comparable with BF-200 ALA and MAL. Dose-
finding studies and larger trials are warranted in the future for HAL.
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Figure legends
Figure 1. Flow-chart of the trial.
117 randomized lesion 
(in 60 patients) at the enrollment 
95 BCC (in 54 patients) completed the study
3 BCC (in 3 patients) excluded, protocol
 not followed
BF-200 ALA 33 BCC:
8 patients with single
18 patients with multiple
All patients attended 3 months follow-up
19 excluded lesion (in 12 patients):
Not BCC in histopathology
HAL 31 BCC:
5 patients single
19 patients with multiple
MAL 31 BCC:
14 patients with single
13 patients with multiple
BF-200 ALA
 30/33 responded BCC
HAL
29/ 31 responded BCC
MAL 
30/31 responded BCC
2 BCC from HAL group:
 Not receiving enough of HAL for PDT II (MAL was used for the 
second treatment)
1 BCC from MAL group:
Patient refused from PDT II due to local reaction from PDT I
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Figure 2. Example lesion with images from all phases of the protocol. The example lesion was 
randomized to the HAL group: A) Clinical image of an sBCC; B) Dermatoscopic image at 
baseline; C) Marking the lesion, treatment area, and diagnostic biopsy site (copied on plastic 
sheets with scaling); D) Histology presenting an sBCC in the diagnostic biopsy; E) Post-treatment 
reaction after PDT I, assessed as strong; F) Clinical image at thee months’ follow-up; cosmetic 
outcome assessed as fair; G) Dermatoscopic image at three months; H) Biopsy site of the control 
biopsy at three months; and I) Histology of the responsive lesion with reactive changes at three 
months.
Figure 3. A) Results for pain during the illumination of the PDT for different photosensitizers. In 
the analyses we named the difference of the recorded VAS in the middle and at the beginning as 4 
min (4 min= VAS of the middle – VAS at the beginning), and the difference of recorded VAS in 
the end and at the beginning was named as 8 min (8 min= VAS of the end – VAS at the 
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Tables
Table 1. Patient and lesion characteristics.
 MAL BF-200 ALA HAL
Patient Characteristics 
Patients 27 26 24
with single lesion 14 8 5
with multiple lesions 13 18 19
Female 10 5 12
Male 17 21 12
Average age in years (range) 71 (47–91) 74 (51–91) 74 (57–91) 
Anamnestic skin phototype   
Phototype I 6 4 7
Phototype II 10 13 8
Phototype III 11 9 9
Phototype IV 0 0 0
Immunosuppression or 
previous radiotherapy 2 1 2
Previous history of skin cancer 
(AK, MB, MM, SCC, BCC) 19 20 19
Previous history of BCC 13 19 16
Lesion characteristics   
Lesions 31 33 31
Location on trunk 25 26 25
Location on extremities 6 7 6
Average treatment area in mm2 
(range) 439 (150–1100) 377 (130–850) 376 (160–750)
New 30 30 29
Recurrent 1 3 2
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